Astonea Labs (BOM:544409) EBIT: ₹55.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544409 Astonea Labs Ltd BOM:544409
12 GF Score
Price ₹273.75
! 4 Warning Signs
View Full Analysis

What is Astonea Labs EBIT?

Astonea Labs BOM:544409 +1.01% 12 EBIT is ₹55.7 Mil as of Mar. 2026. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Astonea Labs's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹55.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹55.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Astonea Labs's annualized ROC % for the quarter that ended in Mar. 2026 was 16.59%. Astonea Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Astonea Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.69%.

Astonea Labs  (BOM:544409) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Astonea Labs's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=206.024 * ( 1 - 19.5% )/( (963.724 + 1035.207)/ 2 )
=165.84932/999.4655
=16.59 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1218.153 - 247.92 - ( 6.509 - max(0, 442.064 - 866.913+6.509))
=963.724

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1462.597 - 425.599 - ( 1.791 - max(0, 678.878 - 980.887+1.791))
=1035.207

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Astonea Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=222.88/( ( (320.642 + max(539.439, 0)) + (387.146 + max(522.949, 0)) )/ 2 )
=222.88/( ( 860.081 + 910.095 )/ 2 )
=222.88/885.088
=25.18 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(564.315 + 263.419 + 0) - (247.92 + 0 + 40.375)
=539.439

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(520.284 + 336.089 + 122.723) - (425.599 + 0 + 30.548)
=522.949

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Astonea Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=55.72/3305.635
=1.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astonea Labs EBIT Related Terms

Astonea Labs EBIT Historical Data

* Premium members only.

The historical data trend for Astonea Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astonea Labs EBIT Chart

Astonea Labs Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
20.55 33.41 81.15 105.37 89.58

Astonea Labs Quarterly Data
Mar22 Mar23 Mar24 Dec24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial 0.00 34.37 25.60 0.00 55.72

BOM:544409 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astonea Labs EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Astonea Labs's EV-to-EBIT falls into.


BOM:544409
12GF Score
Astonea Labs Ltd BOM:544409
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astonea Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹55.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹55.7 Mil mean?
Astonea Labs (BOM:544409) has a EBIT of ₹55.7 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Astonea Labs.
Is Astonea Labs' EBIT too high?
Astonea Labs' current EBIT is ₹55.7 Mil. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' EBIT compare to ZTS?
Astonea Labs' EBIT of ₹55.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Astonea Labs. Astonea Labs's current EBIT is ₹55.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current EBIT of ₹55.7 Mil. The current EBIT is ₹55.7 Mil. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current EBIT is ₹55.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Astonea Labs Business Description

Address SCO 186-187, 2nd Floor, Cabin No. 306, SECTOR 8-C, Sector 8, Chandigarh, HR, IND, 160009
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score

Get the complete analysis for BOM:544409

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹273.75
Price